Beijing Erui Xinyue Secures Tens of Millions in Pre-A+ Financing to Accelerate Exosome-Based Diagnostic Innovation

Recently,Beijing ERXY Technology Co., Ltd. (hereinafter referred to as “ERXY”) announced the successful completion of its Pre-A+ financing round, raising tens of millions of yuan. The funds from this round will continue to be used for the company’s ongoing innovative R&D, market expansion, and team building.

ERXY had just completed its Pre-A financing round in March 2024, and only six months later, it successfully secured additional Pre-A+ funding. This achievement fully demonstrates the market’s high recognition of ERXY’s team and original products, while injecting strong financial support and momentum for the company’s future development.

Since its establishment, ERXY has adhered to the corporate vision of “dedicating itself to exosome applications and serving as a guardian of life and health,” focusing on the research, development, and application of exosome-related technologies. Its wholly-owned subsidiary, Beijing Kaixiang Hongkang Biotechnology Co., Ltd., has independently developed an α-synuclein assay kit based on exosome technology (using magnetic particle chemiluminescent immunoassay), which has successfully received market approval from the Beijing Medical Products Administration for the auxiliary diagnosis of Parkinson’s disease (brand name: Paliming).^TM). ThisThis kit is the world’s first in vitro diagnostic product for Parkinson’s disease based on the detection of plasma-targeted exosomal biomarkers. It has rapidly gained recognition from market demanders since its launch, and its current commercialization progress is excellent.

With this round of financing, ERXY will further optimize its proprietary exosome targeted enrichment technology and accelerate the R&D and commercialization of its diagnostic product pipeline for complex brain-related diseases. In addition, the company will continue to strengthen collaborations with leading research institutions, universities, and medical organizations both domestically and internationally, building an open and shared innovation ecosystem to jointly promote the rapid development of exosome application science.

Driven by the dual forces of capital and innovation, ERXY is steadily advancing into a new phase of development. The successful completion of this Pre-A+ financing round not only affirms ERXY’s dedicated efforts in the field of precision medicine but also reflects strong confidence from the capital market in its future strategic direction and market potential. The company’s management expresses gratitude to both existing and new shareholders for their continued support and will leverage this funding to accelerate the translation of research achievements into clinical applications, facilitate the commercialization of more innovative exosome-based products, and meet the growing public health demands.